Integrative Proteomic Characterization of Human Lung Adenocarcinoma
On July 9, 2020, professor Minjia Tan from Shanghai institute of materia medica of Chinese academy of sciences, professor Ting Xiao from Chinese academy of medical sciences and Peking union medical college, professor Fuchu He and Yi Wang from Beijing institute of lifeomics and professor Jing Li from Shanghai Jiao Tong university co-authored published a paper on Cell. The paper titled Integrative Proteomic Characterization of Human Lung Adenocarcinoma.
The ELISA kit (HSP90aB1, SED522Hu) of Cloud-Clone brand was chosed to determine the concentation of PVR in this article, we are so proud for supporting the reaserchers.
Genomic studies of lung adenocarcinoma (LUAD) have advanced our understanding of the disease’ s biology and accelerated targeted therapy. However, the proteomic characteristics of LUAD remain poorly understood. We carried out a comprehensive proteomics analysis of 103 cases of LUAD in Chinese patients. Integrative analysis of proteome, phosphoproteome, transcriptome, and whole-exome sequencing data revealed cancer-associated characteristics, such as tumor-associated protein variants, distinct proteomics features, and clinical outcomes in patients at an early stage or with EGFR and TP53 mutations. Proteomebased stratifification of LUAD revealed three subtypes (S-I, S-II, and S-III) related to different clinical and molecular features. Further, we nominated potential drug targets and validated the plasma protein level of HSP90b as a potential prognostic biomarker for LUAD in an independent cohort. Our integrative proteomics analysis enables a more comprehensive understanding of the molecular landscape of LUAD and offers an opportunity for more precise diagnosis and treatment.